The data were obtained from IBM MarketScan to be used under specific data use agreement. Although we can not share the data with the readers according to the agreement, readers can request data access to the same data by online application at <https://www.ibm.com/account/reg/us-en/signup?formid=MAIL-watsonhealthna>.

Introduction {#sec007}
============

Using systemic corticosteroids in the treatment of acute respiratory tract infections (ARTIs) in the outpatient settings is not recommended by clinical guidelines \[[@pmed.1003058.ref001]--[@pmed.1003058.ref003]\]. Data from randomized control trials (RCTs) show that systemic steroids are ineffective in the treatment of lower respiratory tract infections \[[@pmed.1003058.ref004]\]. Similar---albeit more limited---data also show the lack of effectiveness of steroid use in the common cold \[[@pmed.1003058.ref005]\] and otitis media \[[@pmed.1003058.ref006]\]. Studies have shown mixed results on whether systemic steroids lead to faster symptom relief in pharyngitis \[[@pmed.1003058.ref007]\], and possibly also in sinusitis \[[@pmed.1003058.ref008]\].

By contrast, one meta-analysis of RCTs showed even a short course of systemic steroids in sinusitis with polyposis could result in a 3-fold increase in the risk of gastrointestinal disturbances and insomnia \[[@pmed.1003058.ref009]\]. An observational study found that acute adverse events associated with short-term use of systemic steroids, including sepsis, venous thromboembolism, and fracture, can occur as early as the first 30 days of drug exposure \[[@pmed.1003058.ref010]\]. Taken together, available evidence and professional society recommendations do not support prescribing systemic steroids for ARTI in ambulatory settings \[[@pmed.1003058.ref001]--[@pmed.1003058.ref003]\].

Despite the lack of clear evidence for this clinical practice, one recent review estimated that 11% of adult outpatients with ARTIs across the US were treated with oral steroids and 23% in the state of Louisiana were treated with injectable steroids \[[@pmed.1003058.ref011]\]. If true, such prescribing trends could be putting tens of thousands of patients at increased risk of adverse events without clear clinical benefits \[[@pmed.1003058.ref001], [@pmed.1003058.ref009], [@pmed.1003058.ref010]\]. However, these prescribing rates were based on survey data, which may be subject to recall inaccuracy, particularly regarding details of medication use, such as dose and duration of the prescription \[[@pmed.1003058.ref012]\]. Since these results were drawn from a limited number of years (2012--2013 for oral steroids and 2014 steroid injections), there was no ability to assess time trends. Finally, the data on injectable steroids were limited to one state, leaving open the question of whether there was any regional variation in clinical practice patterns.

To provide a more comprehensive assessment of US prescribing of systemic steroids for ARTI, we used a large claims database across 10 years with nationwide coverage and stratified patients by whether they received steroids associated with ARTI diagnosis via oral, intravenous, and intramuscular routes. We also sought to determine the regional differences and other predictors associated with this practice, since prior analyses have revealed that treating ARTI with steroid injections might be a common practice in the southern US \[[@pmed.1003058.ref011]\].

Methods {#sec008}
=======

Study design and data sources {#sec009}
-----------------------------

This is a cohort study based on retrospective analysis of a large commercial health insurance database, IBM MarketScan, from January 1, 2007, to December 31, 2016. It contains deidentified records of more than 250 million patients, capturing longitudinal, individual-level administrative claims data from the US, including three components: the Commercial Claims and Encounters Database, the Medicare Supplemental and Coordination of Benefits Database, and the Medicaid Database. Data were drawn from large employers, health plans, and public organizations in the US, providing information on plan enrollment, healthcare utilization and expenditures, demographics, integrated records for inpatient and outpatient events (including diagnosis and procedure codes), and pharmacy dispensings. This database includes individuals with private health insurance coverage but not those uninsured or with public insurance as the primary payor. Electronic outpatient pharmacy dispensing records are considered accurate because pharmacists fill prescriptions with little room for interpretation and are reimbursed by insurers on the basis of detailed, complete, and accurate claims submitted electronically \[[@pmed.1003058.ref013]\]. Pharmacy dispensing information is usually seen as the gold standard of drug exposure information compared to self-reported information \[[@pmed.1003058.ref012]\] or prescribing records in outpatient medical records \[[@pmed.1003058.ref014]\]. The Institutional Review Board of the Brigham and Women's Hospital approved the study protocol and patient privacy precautions. This study is reported as per the REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) guideline ([S1 Checklist](#pmed.1003058.s001){ref-type="supplementary-material"}). All analysis plans and definitions were specified prior to study implementation. The definitions of the study variables were based on literature and validation studies \[[@pmed.1003058.ref011], [@pmed.1003058.ref015]--[@pmed.1003058.ref018]\]. The study protocol is available as [S1 Text](#pmed.1003058.s002){ref-type="supplementary-material"} in the supporting information online.

Study population {#sec010}
----------------

The study population was derived from patients aged 18 or older with an ARTI diagnosis recorded in an ambulatory visit between January 1, 2007, and December 31, 2016, without the same diagnosis recorded in the preceding 180 days. Eligible ARTI diagnoses included acute bronchitis, sinusitis, pharyngitis, otitis media, allergic rhinitis, influenza, pneumonia, and unspecified acute upper respiratory infections. To avoid including injectable or oral steroids prescribed in the context of patients with severe arthritis, we excluded encounters associated with rheumatology or orthopedic services as well as those with diagnoses of noninfectious arthritis or spondylosis on the cohort entry date and the preceding 180 days. We excluded patients if they were in nursing home in the 180 days prior to the cohort entry date (drug exposure data not available for these institutionalized patients). To ensure we have sufficient data to assess baseline comorbidities, patients were required to have continuous insurance enrollment and drug benefit coverage during the 365 days prior to cohort entry date. Patients were excluded if aged 65 or older, owing to their eligibility for the federal Medicare program (IBM MarketScan only has Medicare Supplemental but not fee-for-service Medicare claims). In addition, we excluded patients who were prescribed systemic steroids or with the medical conditions in the 365 days prior to the cohort entry date for which systemic steroids may be appropriate. These conditions include asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, malignant neoplasm, organ transplant, interstitial lung disease, urticaria, rheumatoid arthritis, systemic lupus erythematosus, and systemic vasculitis (see [S1 Text](#pmed.1003058.s002){ref-type="supplementary-material"} for definitions of these conditions).

Patient characteristics {#sec011}
-----------------------

We extracted and adjusted for the following covariates: age, sex, ARTI indications, geographical region, provider type (nurse practitioner, physician assistants, general medicine physicians \[internists or family medicine doctors\], medical specialists, or otolaryngology \[ENT\] doctors versus emergency department \[ED\] physicians), care location (regular office, urgent care, or walk-in retail clinic versus ED), employment status, insurance plan, related prescription drug use (nonsteroidal anti-inflammatory drugs, proton-pump inhibitors, histamine-2-receptor antagonists, antibiotics, antiplatelets, anticoagulants), and multiple comorbidities, including diabetes mellitus, hypertension, stroke, kidney dysfunction, dementia, obesity, heart failure, ischemic heart disease, atrial fibrillation, venous thromboembolism, urinary tract infections, human immunodeficiency virus (HIV) infection/acquired immune deficiency syndrome (AIDS), fractures, prior falls, gastroesophageal reflux disease (GERD), peptic ulcer disease, major bleeding events, bronchiectasis, connective tissue diseases, and remote history of nonseptic arthritis or spondyloarthropathy and a combined comorbidity score \[[@pmed.1003058.ref019]\] (see [S1 Text](#pmed.1003058.s002){ref-type="supplementary-material"} for definitions of these conditions). The baseline assessment period was the 365 days prior to the cohort entry date.

Study outcomes {#sec012}
--------------

The primary outcome was defined as having a dispensing record or a procedure code indicating use of systemic steroids orally and parenterally (including intravenous, intramuscular, and nonspecific injectable forms) within 7 days of cohort entry date. See [S1 Text](#pmed.1003058.s002){ref-type="supplementary-material"} for details of the study outcome definitions. Follow-up began on the cohort entry date and continued until first of occurrence of outcome event, disenrollment from the insurance or drug coverage plan, death, hospitalization, or nursing home admission (IBM MarketScan only has outpatient dispending records that do not capture medication use in the hospital or skilled nursing facility) or 7 days after cohort entry date.

Primary and secondary analysis {#sec013}
------------------------------

The study outcome was measured as proportion per 100 patients. The association between patient characteristics and the outcome was assessed by univariate and multivariate logistic regression. Secondary analyses were conducted to test robustness of our findings. First, we repeated all our analyses after restricting to use of systemic steroids within 3 days of cohort entry. Second, we excluded patients with nasal polyps, since in the field of ENT, systemic steroids are commonly prescribed to treat sinusitis \[[@pmed.1003058.ref020]\], particularly sinusitis with polyposis \[[@pmed.1003058.ref009]\]. All analyses were conducted using the Aetion platform and R, version 3.1.2.5 (R Foundation for Statistical Computing), which has been previously validated for use in observational studies \[[@pmed.1003058.ref021], [@pmed.1003058.ref022]\] and for predicting clinical trial findings \[[@pmed.1003058.ref023]\].

Results {#sec014}
=======

A total of 41,322,229 patients with ambulatory encounters had one of the eligible ARTI diagnoses, and our study population consisted of 9,763,710 patients (mean age 39.6 years, female 56.0%, [Fig 1](#pmed.1003058.g001){ref-type="fig"}). With a mean follow-up of 6.35 days (standard deviation \[SD\] = 1.7 days), 11.8% of patients with an ARTI-related ambulatory visit were prescribed systemic steroids (46.1% parenteral only, 47.3% oral only, 6.6% using both routes; [Table 1](#pmed.1003058.t001){ref-type="table"}). Among systemic steroid users with detailed medication information available, 45.5% were prescribed prednisone equivalents of \<20 mg, 23.5% 20--39 mg, and 30.9% ≥40 mg. Most (84.7%) were prescribed a steroid prescription of 7 days or fewer, 14.8% 8--29 days, and 0.5% ≥30 days ([Table 1](#pmed.1003058.t001){ref-type="table"}).

![Study attrition chart.](pmed.1003058.g001){#pmed.1003058.g001}

10.1371/journal.pmed.1003058.t001

###### Steroid use for ARTIs.

![](pmed.1003058.t001){#pmed.1003058.t001g}

                                                                                           Steroid use within 7 days   Steroid use within 3 days
  ---------------------------------------------------------------------------------------- --------------------------- ---------------------------
  **Total number of patients**                                                             9,763,710                   9,763,710
  **Systemic steroids use, *N* patients**                                                  1,154,378                   1,092,626
  **Prescribing rate, % (95% confidence interval)**                                        11.82 (11.80--11.84)        11.19 (11.17--11.21)
  **Route of administration**                                                                                          
      Parenteral routes alone, *N* (%)                                                     532,142 (46.1)              524,987 (48.0)
      Oral route alone, *N* (%)                                                            545,487 (47.3)              501,601 (45.9)
      Oral + parenteral, *N* (%)                                                           76,749 (6.6)                66,038 (6.0)
  **Daily dose in prednisone equivalents, *N* (%)**[\*](#t001fn001){ref-type="table-fn"}                               
      \<20 mg                                                                              280,704 (45.5)              255,971 (45.6)
      20--39 mg                                                                            144,875 (23.5)              131,962 (23.5)
      ≥40 mg                                                                               190,739 (30.9)              173,995 (31.0)
  **Length of supply dispensed, *N* (%)**[\*](#t001fn001){ref-type="table-fn"}                                         
      ≤7 days                                                                              522,192 (84.7)              479,467 (85.3)
      8--29 days                                                                           91,137 (14.8)               79,964 (14.2)
      ≥30 days                                                                             2,989 (0.5)                 2,497 (0.4)

\*Percent among patients with "dose" and "length of supply dispensed" information.

Abbreviation: ARTI, acute respiratory tract infection

Systemic steroid use by ARTI indication {#sec015}
---------------------------------------

Among patients with an ARTI diagnosis in an outpatient setting, those diagnosed with acute bronchitis was associated with the highest odds of receiving systemic steroid (adjusted odds ratio \[aOR\] 2.70, 95% confidence interval \[CI\] 2.68--2.72, *p* \< 0.001), followed by acute sinusitis (aOR 2.03, 95% CI 2.02--2.04, *p* \< 0.001), pneumonia (aOR 1.80, 95% CI 1.77--1.82, *p* \< 0.001), allergic rhinitis (aOR 1.74, 95% CI 1.72--1.75, *p* \< 0.001), otitis media (aOR 1.43, 95% CI 1.42--1.45, *p* \< 0.001), pharyngitis (aOR 1.42, 95% CI 1.41--1.43, *p* \< 0.001), and acute upper respiratory infections (aOR 1.23, 95% CI 1.22--1.24, *p* \< 0.001). Among those with an ARTI diagnosis, having a diagnosis of influenza was associated with lower odds of receiving systemic steroids (aOR 0.65, 95% CI 0.64--0.66, *p* \< 0.001; [Table 2](#pmed.1003058.t002){ref-type="table"}).

10.1371/journal.pmed.1003058.t002

###### Patient characteristics and association with use of systemic corticosteroids.

![](pmed.1003058.t002){#pmed.1003058.t002g}

  Characteristic                                 Total population, *N* = 9,763,710, *N*   Receiving steroids[\*](#t002fn001){ref-type="table-fn"}, *N* = 1,154,378, *N* (%)   Univariate OR       Multivariate aOR[\*\*](#t002fn002){ref-type="table-fn"}
  ---------------------------------------------- ---------------------------------------- ----------------------------------------------------------------------------------- ------------------- ---------------------------------------------------------
  Age categories                                                                                                                                                                                   
      18 to \<25                                 1,752,290                                184,968 (10.6%)                                                                     Ref                 Ref
      25 to \<35                                 1,975,722                                222,489 (11.3%)                                                                     1.08 (1.07--1.08)   1.07 (1.06--1.08)
      35 to \<45                                 2,231,358                                267,660 (12.0%)                                                                     1.16 (1.15--1.16)   1.17 (1.16--1.18)
      45 to \<55                                 2,167,879                                275,439 (12.7%)                                                                     1.23 (1.23--1.24)   1.25 (1.24--1.26)
      ≥55                                        1,636,461                                203,822 (12.5%)                                                                     1.21 (1.20--1.21)   1.22 (1.21--1.23)
  Sex                                                                                                                                                                                              
      Male                                       4,297,795                                540,236 (12.6%)                                                                     Ref                 Ref
      Female                                     5,465,915                                614,142 (11.2%)                                                                     0.88 (0.88--0.88)   0.87 (0.87--0.88)
  ARTI indication                                                                                                                                                                                  
      Unspecified upper respiratory infections   2,354,975                                223,990 (9.5%)                                                                      0.73 (0.73--0.74)   1.23 (1.22--1.24)
      Otitis media                               248,978                                  30,179 (12.1%)                                                                      1.03 (1.02--1.04)   1.43 (1.42--1.45)
      Sinusitis                                  2,398,502                                359,649 (15.0%)                                                                     1.46 (1.45--1.46)   2.03 (2.02--2.04)
      Pharyngitis                                2,272,142                                243,711 (10.7%)                                                                     0.87 (0.86--0.87)   1.42 (1.41--1.43)
      Allergic rhinitis                          1,498,960                                196,792 (13.1%)                                                                     1.15 (1.15--1.16)   1.74 (1.73--1.75)
      Acute bronchitis                           1,442,379                                260,681 (18.1%)                                                                     1.83 (1.82--1.84)   2.70 (2.68--2.72)
      Pneumonia                                  235,440                                  28,307 (12.0%)                                                                      1.02 (1.01--1.03)   1.80 (1.77--1.82)
      Influenza                                  332,623                                  20,548 (6.2%)                                                                       0.48 (0.47--0.49)   0.65 (0.64--0.66)
  Region                                                                                                                                                                                           
      Northeast                                  1,519,033                                90,238 (5.9%)                                                                       Ref                 Ref
      North Central                              2,231,576                                177,785 (8.0%)                                                                      1.37 (1.36--1.38)   1.41 (1.40--1.42)
      South                                      4,120,036                                768,350 (18.6%)                                                                     3.63 (3.60--3.66)   3.78 (3.75--3.81)
      West                                       1,740,782                                103,579 (6.0%)                                                                      1.00 (0.99--1.01)   1.08 (1.07--1.09)
      Unknown                                    152,283                                  14,426 (9.5%)                                                                       1.66 (1.63--1.69)   1.69 (1.66--1.73)
  Provider type                                                                                                                                                                                    
      General medicine                           8,232,102                                945,074 (11.5%)                                                                     Ref                 Ref
      Medical specialist                         214,225                                  16,995 (7.9%)                                                                       0.66 (0.65--0.67)   0.68 (0.67--0.69)
      ED physician                               559,897                                  82,476 (14.7%)                                                                      1.33 (1.32--1.34)   1.16 (1.15--1.17)
      ENT physician                              218,938                                  37,103 (16.9%)                                                                      1.57 (1.56--1.59)   1.48 (1.46--1.50)
      Nurse practitioner                         372,791                                  53,333 (14.3%)                                                                      1.29 (1.28--1.30)   1.10 (1.08--1.11)
      Physician assistant                        164,030                                  19,308 (11.8%)                                                                      1.03 (1.01--1.04)   1.10 (1.08--1.12)
  Care location                                                                                                                                                                                    
      Regular office visit                       9,034,253                                1,048,476 (11.6%)                                                                   Ref                 Ref
      Urgent care                                328,244                                  48,388 (14.7%)                                                                      1.32 (1.30--1.33)   1.27 (1.26--1.28)
      Walk-in retail clinic                      7,467                                    694 (9.3%)                                                                          0.78 (0.72--0.84)   0.65 (0.60--0.70)
      Emergency room                             393,746                                  56,820 (14.4%)                                                                      1.28 (1.27--1.30)   1.19 (1.18--1.21)
  DM                                             560,839                                  54,566 (9.7%)                                                                       0.79 (0.79--0.80)   0.68 (0.68--0.69)
  HTN                                            1,440,025                                188,226 (13.1%)                                                                     1.15 (1.14--1.15)   1.12 (1.11--1.13)
  Stroke                                         48,340                                   5,651 (11.7%)                                                                       0.99 (0.96--1.02)   0.97 (0.94--1.00)
  Kidney dysfunction                             40,425                                   4,064 (10.1%)                                                                       0.83 (0.81--0.86)   0.93 (0.89--0.96)
  Liver disease                                  129,804                                  14,256 (11.0%)                                                                      0.92 (0.90--0.94)   0.96 (0.94--0.98)
  Dementia                                       11,307                                   1,155 (10.2%)                                                                       0.85 (0.80--0.90)   0.85 (0.80--0.91)
  Obesity                                        312,085                                  39,220 (12.6%)                                                                      1.07 (1.06--1.09)   1.00 (0.99--1.01)
  Heart failure                                  30,396                                   3,259 (10.7%)                                                                       0.90 (0.86--0.93)   1.00 (0.95--1.04)
  Ischemic heart disease                         179,551                                  23,113 (12.9%)                                                                      1.10 (1.09--1.12)   1.02 (1.00--1.04)
  Atrial fibrillation                            46,100                                   4,987 (10.8%)                                                                       0.90 (0.88--0.93)   0.98 (0.95--1.01)
  VTE                                            16,022                                   1,587 (9.9%)                                                                        0.82 (0.78--0.86)   0.93 (0.88--0.99)
  Urinary tract infections                       571,447                                  63,957 (11.2%)                                                                      0.94 (0.93--0.94)   0.94 (0.93--0.95)
  HIV/AIDS                                       16,785                                   1,360 (8.1%)                                                                        0.66 (0.62--0.70)   0.62 (0.59--0.66)
  Fractures                                      118,412                                  13,852 (11.7%)                                                                      0.99 (0.97--1.01)   1.02 (1.01--1.04)
  Falls                                          29,154                                   3,661 (12.6%)                                                                       1.07 (1.03--1.11)   1.03 (1.00--1.07)
  GERD                                           353,109                                  44,529 (12.6%)                                                                      1.08 (1.08--1.09)   0.93 (0.92--0.94)
  Peptic ulcer disease                           19,689                                   2,446 (12.4%)                                                                       1.06 (1.01--1.10)   0.99 (0.95--1.04)
  Major bleeding events                          12,886                                   1,238 (9.6%)                                                                        0.79 (0.75--0.84)   0.86 (0.81--0.91)
  Bronchiectasis                                 1,382                                    109 (7.9%)                                                                          0.64 (0.53--0.78)   0.70 (0.57--0.85)
  Connective tissue diseases                     6,245                                    744 (11.9%)                                                                         1.01 (0.93--1.09)   0.93 (0.86--1.01)
  Use of NSAIDs                                  1,177,851                                151,542 (12.9%)                                                                     1.12 (1.11--1.12)   1.09 (1.08--1.10)
  Use of PPIs                                    672,651                                  89,762 (13.3%)                                                                      1.16 (1.15--1.17)   1.14 (1.13--1.15)
  Use of H2RAs                                   94,435                                   10,486 (11.1%)                                                                      0.93 (0.91--0.95)   0.98 (0.96--1.01)
  Use of antibiotics                             2,930,232                                360,876 (12.3%)                                                                     1.07 (1.06--1.07)   1.10 (1.09--1.10)
  Use of antiplatelets                           90,369                                   12,160 (13.5%)                                                                      1.16 (1.14--1.18)   1.08 (1.06--1.10)
  Use of anticoagulants                          52,308                                   5,354 (10.2%)                                                                       0.85 (0.83--0.87)   0.88 (0.85--0.91)
  Combined comorbidity score category                                                                                                                                                             
      \<1                                        7,625,943                                896,204 (11.8%)                                                                     Ref                 Ref
      1--2                                       1,707,347                                209,643 (12.3%)                                                                     1.05 (1.05--1.06)   0.91 (0.90--0.92)
      2--4                                       380,088                                  43,694 (11.5%)                                                                      0.98 (0.97--0.99)   0.85 (0.84--0.87)
      ≥4                                         50,332                                   4,837 (9.6%)                                                                        0.80 (0.78--0.82)   0.71 (0.69--0.74)
  Employment status                                                                                                                                                                                
      Active full time                           5,508,470                                651,569 (11.8%)                                                                     Ref                 Ref
      Retiree                                    503,273                                  58,215 (11.6%)                                                                      0.97 (0.97--0.98)   0.98 (0.97--0.99)
      Active part-time                           104,025                                  10,259 (9.9%)                                                                       0.82 (0.80--0.83)   0.91 (0.89--0.93)
      Unknown/other                              3,647,942                                434,335 (11.9%)                                                                     1.01 (1.00--1.01)   0.99 (0.99--1.00)
  Insurance plan type                                                                                                                                                                              
      PPO                                        5,960,060                                748,413 (12.6%)                                                                     Ref                 Ref
      Comprehensive                              179,535                                  20,230 (11.3%)                                                                      0.88 (0.87--0.90)   1.07 (1.05--1.09)
      EPO                                        129,760                                  11,460 (8.8%)                                                                       0.68 (0.66--0.69)   0.85 (0.83--0.87)
      HMO                                        1,431,532                                116,018 (8.1%)                                                                      0.61 (0.61--0.62)   0.72 (0.71--0.72)
      POS                                        803,251                                  110,638 (13.8%)                                                                     1.11 (1.10--1.12)   1.14 (1.13--1.14)
      CDHP                                       550,856                                  73,079 (13.3%)                                                                      1.07 (1.06--1.07)   0.94 (0.93--0.94)
      HDHP                                       341,572                                  37,251 (10.9%)                                                                      0.85 (0.84--0.86)   0.82 (0.81--0.83)
      Others/missing                             367,144                                  37,289 (10.2%)                                                                      0.79 (0.78, 0.80)   1.00 (0.99--1.01)
  Year of cohort entry date                                                                                                                                                                       
  2007                                           1,368,068                                143,446 (10.5%)                                                                     Ref                 Ref
  2008                                           1,194,950                                125,948 (10.5%)                                                                     1.01 (1.00--1.01)   1.09 (1.08--1.10)
  2009                                           1,292,822                                124,794 (9.7%)                                                                      0.91 (0.90--0.92)   1.04 (1.03--1.05)
  2010                                           991,226                                  111,076 (11.2%)                                                                     1.08 (1.07--1.09)   1.25 (1.24--1.26)
  2011                                           1,040,685                                110,962 (10.7%)                                                                     1.02 (1.01--1.03)   1.20 (1.19--1.21)
  2012                                           1,104,266                                144,628 (13.1%)                                                                     1.29 (1.28--1.30)   1.44 (1.43--1.45)
  2013                                           837,644                                  103,709 (12.4%)                                                                     1.21 (1.20--1.22)   1.48 (1.47--1.50)
  2014                                           758,101                                  100,744 (13.3%)                                                                     1.31 (1.30--1.32)   1.57 (1.56--1.58)
  2015                                           576,617                                  89,806 (15.6%)                                                                      1.57 (1.56--1.59)   1.76 (1.75--1.78)
  2016                                           599,331                                  99,265 (16.6%)                                                                      1.69 (1.68--1.71)   1.93 (1.91--1.94)

\*Within 7 days of an ARTI.

\*\*Adjusted for all the variables listed in Table 2.

Abbreviations: aOR, adjusted odds ratio; ARTI, acute respiratory tract infections; CDHP, consumer-driven health plan; COBRA, Consolidated Omnibus Budget Reconciliation Act; DM, diabetes mellitus; ED, emergency department; ENT, otolaryngology; EPO, exclusive provider organization; GERD, gastroesophageal reflux disease; H2RA, histamine-2-receptor antagonist; HDHP, high-deductible health plan; HIV/AIDS, human immunodeficiency virus/acquired immune deficiency syndrome; HMO, health maintenance organization; HTN, hypertension; NSAID, nonsteroidal anti-inflammatory drug; POS, point of service; PPI, proton-pump inhibitor; PPO, preferred provider organization; VTE, venous thromboembolism

Geographical variability {#sec016}
------------------------

We found remarkable regional differences. Patients seeking care for ARTI in the South were 3.78 times (95% CI 3.75--3.81, *p* \< 0.001) more likely to be prescribed a systemic steroid than those cared in the Northeast. Such prescribing differences were more pronounced for parenteral steroids than for oral steroids. The aOR of receiving parenteral steroids was 14.48 (95% CI 14.23--14.72, *p* \< 0.001) comparing the South versus Northeast, and the corresponding aOR was 1.68 (95% CI 1.66--1.69, *p* \< 0.001) for oral steroids ([Fig 2](#pmed.1003058.g002){ref-type="fig"} and [Table 3](#pmed.1003058.t003){ref-type="table"}).

![Geographical variability in prescribing systemic steroids for acute respiratory tract infections.\
Source of the base map: <https://www.census.gov/geographies/mapping-files/2017/geo/kml-cartographic-boundary-files.html>.](pmed.1003058.g002){#pmed.1003058.g002}

10.1371/journal.pmed.1003058.t003

###### Associations between geographical region and use of systemic steroids.

![](pmed.1003058.t003){#pmed.1003058.t003g}

  Variable                             aOR (95% CI)
  ------------------------------------ ----------------------
  **Any steroids**                     ** **
      North Central versus Northeast   1.41 (1.40--1.42)
      South versus Northeast           3.78 (3.75--3.81)
      West versus Northeast            1.08 (1.07--1.09)
      Unknown versus Northeast         1.69 (1.66--1.73)
  **Parenteral steroids (IV or IM)**   ** **
      North Central versus Northeast   2.61 (2.57--2.66)
      South versus Northeast           14.48 (14.23--14.72)
      West versus Northeast            2.38 (2.33--2.43)
      Unknown versus Northeast         3.74 (3.62--3.87)
  **Oral steroids**                    ** **
      North Central versus Northeast   1.22 (1.21--1.23)
      South versus Northeast           1.68 (1.66--1.69)
      West versus Northeast            0.84 (0.83--0.85)
      Unknown versus Northeast         1.36 (1.33--1.39)

Adjusted for all the variables listed in [Table 2](#pmed.1003058.t002){ref-type="table"}.

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; IM, intramuscular; IV, intravenous.

Provider type and care location {#sec017}
-------------------------------

Compared to general medicine physicians, ENT specialists were associated with the highest prescribing rate of systemic steroids for ARTI (aOR 1.48, 95% CI 1.46--1.50, *p* \< 0.001), followed by ED physicians (aOR 1.16, 95% CI 1.15--1.17, *p* \< 0.001), physician assistants (aOR 1.10, 95% CI 1.08--1.12, *p* \< 0.001), nurse practitioners (aOR 1.10, 95% CI 1.08--1.11, *p* \< 0.001), and medical specialists, who had a lower rate (aOR 0.68, 95% CI 0.67--0.69, *p* \< 0.001; [Table 2](#pmed.1003058.t002){ref-type="table"}). Compared to ambulatory care office visits, systemic steroids were more likely to be prescribed to treat ARTIs in urgent care (aOR 1.27, 95% CI 1.26--1.28, *p* \< 0.001), followed by ED (aOR 1.19, 95% CI 1.18--1.21, *p* \< 0.001), and they are less likely to be prescribed in walk-in retail clinics (aOR 0.65, 95% CI 0.60--0.70, *p* \< 0.001; [Table 2](#pmed.1003058.t002){ref-type="table"}).

Comorbidities {#sec018}
-------------

Individual comorbidities negatively associated with odds of systemic steroid prescribing were diabetes, kidney dysfunction, liver disease, dementia, venous thromboembolism, major bleeding events, GERD, bronchiectasis, urinary tract infections, HIV/AIDS, and bronchiectasis. Using a validated combined comorbidity score \[[@pmed.1003058.ref019]\], patients with more comorbidities were associated with a lower odds of receiving systemic steroids. Use of antibiotics, proton-pump inhibitors, antiplatelets, and nonsteroidal anti-inflammatory drugs were positively associated with odds of systemic steroid prescribing ([Table 2](#pmed.1003058.t002){ref-type="table"}).

Time trend {#sec019}
----------

Prescribing of systemic, parenteral, and oral steroids for ARTI all increased from 2007 to 2016 (*p* \< 0.001 for all three, [Fig 3](#pmed.1003058.g003){ref-type="fig"}). The prescribing rate for systemic steroids in 2016 was almost double that of 2007 (aOR 1.93, 95% CI 1.91--1.94). The corresponding aOR was 1.33 (95% CI 1.31--1.35) for parenteral steroids and 2.74 (95% CI 2.71--2.78) for oral steroids ([Fig 3](#pmed.1003058.g003){ref-type="fig"}).

![Time trend of prescribing rates of systemic steroids for acute respiratory tract infections.](pmed.1003058.g003){#pmed.1003058.g003}

Sensitivity analysis {#sec020}
--------------------

When restricting to systemic steroid use within the first 3 days of ARTI diagnosis, the prescribing patterns were similar to that for steroid use in 7 days of ARTI diagnosis ([Table 1](#pmed.1003058.t001){ref-type="table"}), and the results of all analyses were similar (see [S1](#pmed.1003058.s003){ref-type="supplementary-material"} and [S2](#pmed.1003058.s004){ref-type="supplementary-material"} Tables). After excluding patients with nasal polyps, our estimates for all analyses were not materially changed, and ENT physicians were still associated with an aOR of prescribing systemic steroids of 1.47 (95% CI 1.45--1.48) when compared to the general practitioners.

Discussion {#sec021}
==========

Using a national sample of privately insured US patients over the last decade, we found 11.8% of patient encounters with ARTI resulted in receiving systemic steroid treatments. Such prescribing has almost doubled from 2007 to 2016, with patients far more likely to receive this care---particularly injectable steroids---in the southern US, even though use of systemic steroid treatments for ARTIs lacks clear scientific justification. Providers in the ED and urgent care, as well as ENT specialists, were more likely to be prescribers. Use of steroids for ARTIs has been increasing over time, with as many as 16.3% of US patients with an ARTI diagnosis aged 18--64 years---or 10.6 million people---receiving such treatment in 2016.

Our estimates of systemic steroid use for ARTI were consistent with a prior study that used national survey data and local administrative data \[[@pmed.1003058.ref011]\]. We further quantified such prescribing by route of administration and found a disproportionally high prescribing rates in the southern states than in other states, especially for the parenteral routes \[[@pmed.1003058.ref011]\]. We did not find any meaningful differences in patient demographics, ARTI indications, care settings, provider types, and patient comorbidities that can explain the remarkable geographical variability in steroid use for ARTI ([S3 Table](#pmed.1003058.s005){ref-type="supplementary-material"}). To put geographical variations of patient characteristics into perspective, the observed risk ratio of 3.78 associated with the southern region could only be fully explained by an unmeasured confounder that was associated with both the southern region and steroid prescribing by a risk ratio of 7.02-fold each \[[@pmed.1003058.ref024]\], above and beyond the adjusted factors. By the same formula, only an unmeasured confounder associated with both the southern region and steroid prescribing by a risk ratio of 28.45-fold each could account for the 14-fold increased odds of receiving parenteral steroids in the South \[[@pmed.1003058.ref024]\]. The aORs comparing the southern region to all other regions were far smaller than these required thresholds ([S3 Table](#pmed.1003058.s005){ref-type="supplementary-material"}). Given lack of convincing evidence to guide such practice, it is not surprising we did not identify any objective factors associated with it. The regional difference therefore are most likely related to local culture, physician preferences, and patient expectations. There were some similarities of the regional differences in the use of systemic steroids versus antibiotics for ARTI, in which the highest prescribing rates of both systemic steroids and antibiotics for ARTI were observed in the southern states \[[@pmed.1003058.ref025]\]. Since both practices are potentially inappropriate, future research is warranted to investigate the possible impact and interactions of the two practices on clinical outcomes by region.

There was very little evidence supporting prescribing systemic steroids for ARTI. As for oral steroids, data from RCTs have shown that treating pharyngitis with systemic steroids may shorten time to resolution of sore throat \[[@pmed.1003058.ref007]\]. For acute sinusitis, meta-analysis of RCTs has deemed systemic steroids to be ineffective as monotherapy, and the small benefit in symptom relief when used as an adjuvant therapy with antibiotics could possibly be explained by attrition bias \[[@pmed.1003058.ref008]\]. An RCT also revealed that systemic steroids are ineffective in the treatment of lower respiratory tract infections \[[@pmed.1003058.ref004]\]. All the prior RCTs investigating systemic steroid use in community-acquired pneumonia recruited hospitalized patients; among them, steroids as adjuvant therapy to proper antibiotics were shown to reduce mortality and morbidity only in patients with severe pneumonia but not for those with nonsevere pneumonia, casting doubt on generalizing the effectiveness to the ambulatory settings \[[@pmed.1003058.ref026]\]. There were very limited RCT data in steroid use in common cold (only intranasal steroids were studied, which was shown to be ineffective \[[@pmed.1003058.ref005]\]) and otitis media (only pediatric population was studied, which was found to be ineffective \[[@pmed.1003058.ref006]\]). With questionable benefits and substantial risks \[[@pmed.1003058.ref009], [@pmed.1003058.ref010]\], treating ARTI with systemic steroids has not been recommended by clinical guidelines \[[@pmed.1003058.ref001]\].

Systemic steroid prescribing rates were the highest in urgent care or ED. Because the only demonstrated benefits associated with systemic steroid use in ARTI is symptomatic relief, it is possible people with more severe symptoms seek medical attention in urgent care or ED settings, leading to steroid prescriptions. We found that people with more complex comorbidities are less likely to receive systemic steroids for ARTI. It is plausible that providers are less inclined to prescribe steroids to these vulnerable populations who are more susceptible to developing serious side effects from systemic steroid use \[[@pmed.1003058.ref027], [@pmed.1003058.ref028]\]. However, adjusting for individual comorbidities, older age was predictive of more steroid prescribing in ARTI. As older age is a strong risk factor for steroid-related complications, including gastrointestinal bleeding \[[@pmed.1003058.ref029]\], sepsis \[[@pmed.1003058.ref030]\], venous thromboembolism \[[@pmed.1003058.ref031]\], and osteoporotic fracture \[[@pmed.1003058.ref032]\], these findings convey an urgent need to reduce this potentially harmful practice.

We also found a steadily increasing trend in prescribing systemic steroids from 2007 to 2016 that was more pronounced for oral than parenteral steroids. The studies showing systemic steroids can lead to faster symptom relief in some limited ARTI indications \[[@pmed.1003058.ref007]--[@pmed.1003058.ref009]\] may have encouraged use over time for patients with more severe symptoms. Other factors contributing to this trend could include low prices for steroid prescriptions---for example, numerous oral steroids are often available on \$4 generic lists that pharmacies started promoting about a decade ago \[[@pmed.1003058.ref033]\]---and payers' increasingly choosing to integrate patient quality ratings into provider reimbursement. Surveys show that patients often feel better about their physician visits when that visit results in a prescription or other interventions \[[@pmed.1003058.ref034]\], although in this case, the prescriptions do not have supporting evidence behind them.

Our results call for an effective medical education program to help disseminate the messages about the potential risks and limited benefits of steroid prescribing in the context of ARTIs, faithfully reflecting totality of the existing evidence. For example, both physicians and patients should be well informed that treating pharyngitis with systemic steroids may shorten time to resolution of sore throat by about 11 hours \[[@pmed.1003058.ref007]\], at the cost of some potentially serious side effects, including gastrointestinal disturbances, insomnia, sepsis, venous thromboembolism, and fracture, which can occur as early as the first 30 days after a short-term use \[[@pmed.1003058.ref009], [@pmed.1003058.ref010]\]. Investing in medical education programs to help transform clinical practice in this area would improve patient outcomes and reduce health system spending on managing the side effects of such non-evidence-driven care.

Our study has some limitations. First, our primary outcome was systemic steroid prescription within 7 days of ARTI diagnosis, and the indication was not written directly on the prescription or dispensing record. It is possible that some of the prescriptions were not intended to treat ARTI. To minimize erroneous association with the steroid use, we excluded patients with an extensive list of medical conditions for which systemic steroid use may be appropriate as well as those exposed to systemic steroids in the prior year. Also, our sensitivity analysis assessing steroid use within 3 days of ARTI diagnosis showed very similar results ([Table 1](#pmed.1003058.t001){ref-type="table"}). Second, we could not stratify our analysis by severity of symptoms because such information was not available in the IBM MarketScan database. However, this limitation should not affect the implication of our findings, as evidence suggests prescribing systemic steroids for ARTI may not be associated with a favorable risk-to-benefit ratio regardless of symptom severity \[[@pmed.1003058.ref009], [@pmed.1003058.ref010]\]. Third, since we excluded a wide range of steroid-indicated conditions, including asthma, chronic obstructive pulmonary disease, malignancy, and many allergic and autoimmune diseases, our findings cannot be generalized to patients with these conditions as comorbidities. The definitions of the conditions used for inclusion/exclusion criteria were based on prior literature and validation studies \[[@pmed.1003058.ref011], [@pmed.1003058.ref015]--[@pmed.1003058.ref018]\]. As none of these algorithms is perfect, misclassification of our study variables is possible. However, given that we excluded those who received systemic steroids in the year prior to the cohort entry, our estimated prescribing rates for ARTI is probably conservative. Lastly, our findings are based on patients aged between 18 and 64 years with commercial medical insurance and may not be generalizable to older populations or patients with public health insurance coverage.

Despite these limitations, we found 11.8% of ARTI encounters results in patients being treated with systemic steroids. Such prescribing has been steadily increasing from 2007 to 2016 and is far more common in the southern US. These findings call for an effective medical education program to reduce this practice, which lacks clear scientific justification.
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\[LINK\]
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5- Please place the study design in the subtitle (ie, after a colon).
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12- In the Introduction, please cite a specific guideline or guidelines re prescribing, rather than \"an observational study".

13- Please include information on ethical approval informed consent in the Methods.
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15- Though perhaps not the intent, the language of \"non evidence based\" can be read in rather a sanctimonious way, considering that some of the prescribing appears to be for symptomatic relief in the ED. In the discussion, it could be worth mentioning the alternatives available to doctors for provision of symptomatic relief.

Comments from the reviewers:

Reviewer \#1: Alex McConnachie, Statistical Review

The article by Lin et al presents an analysis of routine data from approximately 10 million people, to investigate the use of systemic steroids for acute respiratory tract infections over a 10-year period in the US. This review is primarily focused on the use of statistics in the paper.

The description of the study population is good, giving a clear description of those included and excluded, and why. There is a long list of patient and encounter characteristics that were used to adjust the analyses, all of which appear sensible things to look at. The study outcome is clearly defined. Even though the length of follow-up is not the same for every study participant, given the size of the dataset, and the average length of follow-up, the use of logistic regression is justified. The sensitivity analyses also seem reasonable.

When looking at the associations between ARTI conditions and systemic steroid prescribing, care must be taken, since every patient had at least one condition. So, to say that having influenza was associated with a reduced likelihood of a prescription may not be accurate, since those without a diagnosis of influenza must have had one of the other diagnoses.

Data are presented for parenteral and oral steroids, but the methods section describes extracting the route of administration as oral, intravenous, or intramuscular. Is there a reason for this?

The sensitivity analysis results are reportedly similar to the main analysis, but these results are not shown. Would it be possible to include these results in the supplement, just for completeness?

Given that one of the most striking findings of this analysis is the geographical variation in prescribing rates, I wonder whether it would be of value to carry out stratified analyses, or even to formally test whether the predictors of prescribing vary between geographical regions. For example, the patterns of prescribing in relation to age and gender could be very different in different regions. It may be too much for this paper, but perhaps worth considering.

Table 2 is fine, but I think it could be improved. What matters are the numbers of patients in each row category, and the number and percentage who received a steroid prescription. E.g. for the age group \"18 - \<25\", I would show in the first column, that there were 1,752,290 people in this category, and in the second column, show that 184,968 (10.6%) received a steroid. Since the outcome is receiving a steroid prescription, then as a reader I want to see how the percentage with the outcome varies according to patient and encounter characteristics.

Reviewer \#2: This paper uses a large medications database to explore the use of oral and systemic steroids for ARTI in the US. It is a clear and well written paper. I have a number of minor \'style comments\' detailed below. For the non US reader a slightly fuller explanation of the claims database might be helpful - what proportion of consultations in the US are captured by this. What is missed in such a dataset (non-insured/other settings?)

The Background is appropriate and justifies the study.

Methods- population at risk clearly described and appropriate for the question. The analysis adjusted for many co-variates although these were not clearly justified in the manuscript, a sentence to justify these would be helpful.

Results

The results are clearly stated including those from the sensitivity analyses.

Discussion.

The main results are summarised clearly with additional information to enable the reader to estimate the population level impact of the steroid prescribing.

The comparison with other literature is appropriate as is the exploration of potential explanations for the variation by setting.

The final paragraph on p 11 (potential explanations) might be better placed later in the manuscript.

Regarding the first paragraph on page 12 I think it is sufficient to say that the issue should be addressed, and appropriate interventions developed using the models shown to be effective in antibiotic stewardship rather than selecting academic detailing for specific mention.

The limitations section appropriately highlights the reliance on temporal association but replication of findings using the more restricted timeframe is reassuring

Style Comments

Background

I suggest leaving the reader to draw conclusions about whether steroid prescribing is questionable and that the first sentence could simply read

In the outpatient settings is not recommended in clinical guidelines

Para 3- why not say Despite the lack of evidence one recent review....

Some minor wording comments, I dont think \'drastic\' is needed as a descriptor and when discussing steroids in sinusitis- the treatment effect could simply be explained rather than \'explained away\'

Reviewer \#3: This study examines the prevalence and determinants, with a primary focus on geography, of systemic corticosteroid use among over 9.7 million patients with acute respiratory tract infections (ARTIs) meeting inclusion criteria in the United States using large administrative claims databases from 2007-2016.

1\. Novelty: Previous studies have demonstrated high levels of systemic corticosteroid use among patients with ARTI with rates comparable to those demonstrated in this study, albeit using different methods. Could the authors highlight in the discussion where this study truly adds novel findings?

2\. Potential for misclassification: The use of systemic corticosteroids for the treatment of ARTI was the primary outcome. The potential for misclassification may be problematic at the level of the ARTI diagnosis itself and the at the level of systemic corticosteroid indication. The diagnosis of ARTI included acute bronchitis, sinusitis, pharyngitis, otitis media, allergic rhinitis, influenza, pneumonia, and unspecified acute upper respiratory infections. Have the codes for identifying these conditions been validated? If so, please provide references. The assessment indication of systemic corticosteroid involved numerous inclusion / exclusion criteria since systemic corticosteroids are widely used for a variety of indications. Has the approach to assessing systemic corticosteroid use for the purpose of treating ARTIs been validated? If so, please provide a reference. The authors do acknowledge potential misclassification as a limitation.

3\. Generalizability: Approximately 9.7 million patients of over 41 million patients met the inclusion / exclusion criteria (i.e. 24%), which may limit generalizability. Have the authors investigated the generalizability of their findings? They have noted this as a limitation in the discussion section.

4\. A priori definition of outcomes and exposure assessment: Geography was a key exposure that was being assessed yet it is poorly described in the methods section. How was geography defined? It\'s assumed that this was done at the state level. Did all states have comparable database coverage (i.e. was sampling similar from state to state)? Further, were there any pre-specified hypotheses? Tables 2 and 3 report a very large number of statistical tests. If not, I worry this may simply be a \'fishing expedition\' that would be subject to false associations related to multiple hypothesis testing. Inclusion of a formal analysis plan in the methods section is highly advised.
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Dear Dr. Lin,

Thank you very much for re-submitting your manuscript \"Prescribing Systemic Steroids for Acute Respiratory Tract Infections in US Outpatient Settings\" (PMEDICINE-D-19-02226R1) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by xxx reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.
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In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.
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